

# Jingqin Luo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8502205/publications.pdf>

Version: 2024-02-01

108  
papers

8,014  
citations

117571

34  
h-index

53190

85  
g-index

114  
all docs

114  
docs citations

114  
times ranked

13793  
citing authors

#	ARTICLE	IF	CITATIONS
1	CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models. <i>Cancer Research</i> , 2014, 74, 5057-5069.	0.4	1,030
2	Whole-genome analysis informs breast cancer response to aromatase inhibition. <i>Nature</i> , 2012, 486, 353-360.	13.7	922
3	Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1380-1388.	3.0	566
4	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
5	Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. <i>Immunity</i> , 2017, 47, 323-338.e6.	6.6	499
6	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031. <i>Journal of Clinical Oncology</i> , 2011, 29, 2342-2349.	0.8	470
7	TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. <i>Cell</i> , 2020, 182, 886-900.e17.	13.5	309
8	Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. <i>Nature Communications</i> , 2016, 7, 11762.	5.8	290
9	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. <i>Cell</i> , 2020, 183, 1436-1456.e31.	13.5	273
10	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	0.8	254
11	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4055-4065.	3.2	243
12	Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	230
13	Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. <i>Cell</i> , 2018, 172, 534-548.e19.	13.5	197
14	Sex differences in cancer mechanisms. <i>Biology of Sex Differences</i> , 2020, 11, 17.	1.8	169
15	Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. <i>Journal of Clinical Investigation</i> , 2014, 124, 4123-4133.	3.9	115
16	An NAD <sup>+</sup> -dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8247-E8256.	3.3	101
17	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , 2018, 9, 3476.	5.8	89
18	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1583-1591.	3.2	86

#	ARTICLE	IF	CITATIONS
19	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. <i>Nature Communications</i> , 2020, 11, 2156.	5.8	83
20	A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2015, 11, 1809-1821.	2.9	82
21	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914.	0.2	74
22	A Quantitative Histomorphometric Classifier (QuHbIC) Identifies Aggressive Versus Indolent p16-Positive Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 128-137.	2.1	73
23	A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 72-80.	2.0	67
24	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	5.8	58
25	Youden Index and Associated Cut-Points for Three Ordinal Diagnostic Groups. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2013, 42, 1213-1234.	0.6	56
26	The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients. <i>Cancer Research</i> , 2015, 75, 16-21.	0.4	56
27	Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 443-452.	1.1	54
28	Sexual dimorphism in glioma glycolysis underlies sex differences in survival. <i>JCI Insight</i> , 2017, 2, .	2.3	54
29	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. <i>Breast Cancer Research</i> , 2017, 19, 123.	2.2	53
30	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. <i>Cancer Research</i> , 2018, 78, 2732-2746.	0.4	52
31	Urinary Concentrations of Aquaporin-1 and Perilipin-2 in Patients With Renal Cell Carcinoma Correlate With Tumor Size and Stage but not Grade. <i>Urology</i> , 2014, 83, 256.e9-256.e14.	0.5	43
32	Tumor Cell Anaplasia and Multinucleation Are Predictors of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma, Including Among Just the Human Papillomavirus-Related Cancers. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1036-1046.	2.1	41
33	Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 223-229.	12.5	38
34	Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1665-1675.	1.9	38
35	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. <i>Neurology</i> , 2020, 95, e3104-e3116.	1.5	35
36	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31

#	ARTICLE	IF	CITATIONS
37	Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. <i>Cancer Research</i> , 2022, 82, 155-168.	0.4	29
38	Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab041.	0.4	28
39	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 589-597.	0.4	25
40	Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	24
41	Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	1.1	24
42	Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary. <i>Cancers</i> , 2021, 13, 3795.	1.7	22
43	PDE7B Is a Novel, Prognostically Significant Mediator of Glioblastoma Growth Whose Expression Is Regulated by Endothelial Cells. <i>PLoS ONE</i> , 2014, 9, e107397.	1.1	22
44	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	1.5	20
45	GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. <i>Scientific Reports</i> , 2020, 10, 9027.	1.6	20
46	Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 344-352.	0.4	20
47	Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. <i>Journal of Clinical Oncology</i> , 2021, 39, 4020-4028.	0.8	20
48	Cancer incidence and mortality rates and trends in Trinidad and Tobago. <i>BMC Cancer</i> , 2018, 18, 712.	1.1	19
49	ABCG1 maintains high-grade glioma survival <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 23416-23424.	0.8	18
50	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	0.6	17
51	A prognostic gene expression signature for oropharyngeal squamous cell carcinoma. <i>EBioMedicine</i> , 2020, 61, 102805.	2.7	16
52	Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4. <i>Cancer Research</i> , 2017, 77, 1416-1426.	0.4	13
53	A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. <i>European Journal of Cancer</i> , 2020, 137, 1-9.	1.3	13
54	Long non-coding RNA LINC00261 / LINC00261 is associated with lung adenocarcinoma prognosis. <i>Heliyon</i> , 2020, 6, e03521.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008, 112, 371-371.	0.6	13
56	Bivariate correlation coefficients in family-type clustered studies. <i>Biometrical Journal</i> , 2015, 57, 1084-1109.	0.6	12
57	Preclinical PERCIST and 25% of SUV <sub>max</sub> Threshold: Precision Imaging of Response to Therapy in Co-clinical <sup>18</sup> F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. <i>Journal of Nuclear Medicine</i> , 2020, 61, 842-849.	2.8	12
58	Increased breast tissue receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. <i>Oncotarget</i> , 2017, 8, 73787-73792.	0.8	12
59	Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. <i>Oncotarget</i> , 2018, 9, 23018-23028.	0.8	12
60	Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	12
61	Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. <i>Medical Physics</i> , 2017, 44, 962-973.	1.6	11
62	Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 571-580.	1.1	11
63	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 147-161.	1.2	11
64	A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy. <i>Oncologist</i> , 2018, 23, 760-e76.	1.9	11
65	A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 193-200.	1.0	11
66	A MicroRNA Expression Signature as Prognostic Marker for Oropharyngeal Squamous Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 752-759.	3.0	10
67	Circulating Receptor Activator of Nuclear Factor- $\kappa$ B (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women. <i>Cancer Prevention Research</i> , 2018, 11, 789-796.	0.7	9
68	$\beta$ -III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. <i>Neuro-Oncology</i> , 2018, 20, 858-860.	0.6	8
69	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 3857.	1.7	8
70	A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 24250-24261.	0.8	8
71	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 2570-2581.	0.4	8
72	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018, 59, 357-362.	0.6	7

#	ARTICLE	IF	CITATIONS
73	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 1448-1457.	0.4	7
74	A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. <i>Npj Breast Cancer</i> , 2022, 8, 35.	2.3	7
75	Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. <i>BMC Medical Research Methodology</i> , 2017, 17, 124.	1.4	6
76	Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2055-2061.	1.1	6
77	Joanne Knight Breast Health Cohort at Siteman Cancer Center. <i>Cancer Causes and Control</i> , 2022, 33, 623-629.	0.8	6
78	Linear combinations of multiple outcome measures to improve the power of efficacy analysis—Application to clinical trials on early-stage Alzheimer's disease. <i>Biostatistics and Epidemiology</i> , 2017, 1, 36-58.	0.4	5
79	Characteristics of male triple negative breast cancer: A population-based study. <i>Breast Journal</i> , 2020, 26, 1748-1755.	0.4	5
80	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3988-3988.	0.6	5
81	Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments. <i>European Journal of Radiology</i> , 2021, 145, 110029.	1.2	5
82	Optimizing parameters in clinical trials with a randomized start or withdrawal design. <i>Computational Statistics and Data Analysis</i> , 2014, 69, 101-113.	0.7	4
83	Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER. <i>Cancer Research</i> , 2021, 81, CT026-CT026.	0.4	4
84	A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS664-TPS664.	0.8	4
85	SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. <i>Scientific Reports</i> , 2020, 10, 15890.	1.6	3
86	The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. <i>BMC Cancer</i> , 2021, 21, 285.	1.1	3
87	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac002.	0.4	3
88	Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case—Application to the early diagnosis of Alzheimer disease. <i>Statistical Methods in Medical Research</i> , 2018, 27, 701-714.	0.7	2
89	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. <i>Journal of Applied Statistics</i> , 0, , 1-25.	0.6	2
90	A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11583-TPS11583.	0.8	2

#	ARTICLE	IF	CITATIONS
91	A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-17, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.. Journal of Clinical Oncology, 2021, 39, 2040-2040.	0.8	2
92	Does circulating progesterone mediate the associations of single nucleotide polymorphisms in progesterone receptor (PGR)-related genes with mammographic breast density in premenopausal women?. Discover Oncology, 2021, 12, 47.	0.8	2
93	Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1) Tj ETQq1 1 0.784314 rgBT /Ov glioblastoma: NCT03532295.. Journal of Clinical Oncology, 2022, 40, 2058-2058.	0.8	2
94	Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2070-TPS2070.	0.8	1
95	Whole genome sequencing to characterize luminal-type breast cancer.. Journal of Clinical Oncology, 2012, 30, 503-503.	0.8	1
96	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limitsâ€™Application to diagnosing early stage Alzheimer disease. Statistical Methods in Medical Research, 2022, 31, 882-898.	0.7	1
97	A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2022, 40, TPS1128-TPS1128.	0.8	1
98	P4â€™083: RACIAL DIFFERENCES OF INCIDENT ALZHEIMER'S DISEASE AS A FUNCTION OF APOE4. Alzheimer's and Dementia, 2018, 14, P1467.	0.4	0
99	Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer. Statistics in Biopharmaceutical Research, 2019, 11, 210-219.	0.6	0
100	Orderings of biomarker changes for Alzheimer disease in cognitively normal individuals from 18 to 101 years of age. Alzheimer's and Dementia, 2020, 16, e043187.	0.4	0
101	Clinical and pathological characteristics of breast cancer with resected brain metastasis.. Journal of Clinical Oncology, 2021, 39, 1089-1089.	0.8	0
102	Prognostic Factors Influencing Survival in Solitary Plasmacytoma: A SEER Database Analysis.. Blood, 2008, 112, 1670-1670.	0.6	0
103	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. Blood, 2008, 112, 4427-4427.	0.6	0
104	Retrospective analysis of adjuvant chemotherapy for patients with soft tissue sarcomas at Washington University in St. Louis.. Journal of Clinical Oncology, 2013, 31, e21501-e21501.	0.8	0
105	A co-clinical phase II trial of carboplatin and docetaxel as neoadjuvant treatment for triple negative breast cancer with genomic discovery analysis.. Journal of Clinical Oncology, 2016, 34, TPS1099-TPS1099.	0.8	0
106	The association between neutrophil to lymphocyte ratio and overall survival in patients with triple-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, e12591-e12591.	0.8	0
107	Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6<i>i</i>). Cancer Research, 2022, 82, P2-07-01-P2-07-01.	0.4	0
108	Longitudinal cascades of Alzheimer disease biomarkers across the entire adult lifespan among cognitively normal adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0